AlloVir’s IPO Raises $276M to Test Cell Therapies in Transplant Patients

AlloVir’s IPO Raises $276M to Test Cell Therapies in Transplant Patients

Source: 
Xconomy
snippet: 

AlloVir is the latest biotech company to go public, raising about $276.3 million to pull its cell therapies off the shelf and run multiple clinical trials testing them in stem cell and organ transplant patients.